Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has entered into $15-million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the University in the areas of scientific research, clinical development and clinical care and policy.
Subscribe to our email newsletter
Under the terms of the agreement, Pfizer will pay Pennsylvania School of Medicine $15 million over a three-year period, during which time scientists from Pfizer and Pennsylvania’s School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas.
Project proposals will be solicited and reviewed by a committee with representation from both parties. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas.
Pfizer and the University of Pennsylvania School of Medicine will develop an initiative to improve the management of cardiovascular risk and patient adherence to treatments, among patients currently served by the University of Pennsylvania’s Health System
In addition, Pfizer and the University will work together to examine current policy and practices around topics of mutual interest, including ongoing education on new therapeutics for physicians.
Martin Mackay, president of global R&D at Pfizer, said: “This collaboration provides an opportunity for Pfizer and the University of Pennsylvania School of Medicine to build and implement a new model for interactions between industry and academic medical centers.”